Effects of Pioglitazone in Calcific Aortic Valve Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT05875675

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05875675
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05875675. Randomized; double masking; primary purpose prevention. Start 2023-07-01 (anticipated); primary completion 2025-07-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Pioglitazone in Calcific Aortic Valve Disease
Condition
Calcification of Aortic Valve
Condition
Aortic Valve Stenosis
Intervention (Drug)
Drug: Pioglitazone Oral Tablet
Intervention (Dietary supplement)
Placebo
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (class: other)

Record details

Record id
cardio:ct-nct05875675
Content hash
f52231c8760290f649980f65ed0f55514ba103c432a6f69ef6a3c152a0d0e33f